Antigen expression and heterogeneity have been shown to be a mechanism of resistance in preclinical studies as described in the JIMT1 lines (resistant cell lines), where xenograft tumours treated with T-DM1 exhibited lower HER2 expression, which is associated with higher relapse rates and lower survival rates [118]. Here, ERBB2 is linked to neoplasm.